Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients
Abstract
Hydroxychloroquine is used extensively in the treatment of systemic lupus erythematosus, not only for its benefit for cutaneous and musculoskeletal lupus, but also for its role in preventing flares, preventing renal and central nervous system lupus, and improving survival rates. Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus. This article reviews its possible role as an antithrombotic drug in the general population, in systemic lupus erythematosus, and in patients with antiphospholipid antibodies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Current recommendations advise hydroxychloroquine for SLE patients with persistent moderate-to-high antiphospholipid antibodies or positive lupus anticoagulant for primary prevention (grade 1B to 2B), based on its other benefits in SLE and thrombosis.
“HCQ treatment is currently recommended for SLE patients with persistent moderate-high aPL Ab or LAC+ for primary prevention (grade 1B to 2B recommendation) based on the other beneficial effects of HCQ in SLE (12, 13) and thrombosis (14).”
Retrospective studies in SLE have shown that hydroxychloroquine reduces the risk of thrombosis.
“Hydroxychloroquine (HCQ) has been shown to decrease aPL titers in laboratory studies, and to decrease thrombosis risk in systemic lupus erythematosus (SLE) patients in retrospective studies.”
The citation lists haven’t been fetched yet
References 44 · Cited by 206
- Authors
- Petri, M.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Petri, Michelle
- ORCID
- Petri, Michelle
- Venue
- Current Rheumatology Reports
- Published
- 2010-10-27
- Volume
- 13
- Issue
- 1
- Pages
- 77-80
- ISSN
- 1523-3774 (ISSN-L)
- 1534-6307
- OpenAlex
- W1991433622
- Cited by
- 206
- References
- 44
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 16 · 2023: 8 · 2022: 13 · 2021: 24 · 2020: 34 · 2019: 8 · 2018: 16 · 2017: 5 · 2016: 17 · 2015: 10 · 2014: 16 · 2013: 11 · 2012: 10
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Rheumatology Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- hydroxychloroquine, thromboprophylaxis, systemic lupus erythematosus, antiphospholipid antibodies, antithrombotic agents, cardiovascular risk factors, hyperlipidemia, diabetes mellitus, lupus flares
- MeSH terms
- Enzyme Inhibitors, Humans, Hydroxychloroquine, Lupus Erythematosus, Systemic, Thrombosis, Antiphospholipid Syndrome, Antibodies, Antiphospholipid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
